Pain in amyotrophic lateral sclerosis: a narrative review

다국어 초록 (Multilingual Abstract)

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative condition characterized by loss of motor neurons, resulting in motor weakness of the limbs and/or bulbar muscles. Pain is a prevalent but neglected symptom of ALS, and it has a significant negative impact on the quality of life of patients and their caregivers. This review outlines the epidemiology, clinical characteristics, underlying mechanisms, and management strategies of pain in ALS to improve clinical practice and patient outcomes related to pain. Pain is a prevalent symptom among patients with ALS, with a variable reported prevalence. It may occur at any stage of the disease and can involve any part of the body without a specific pattern. Primary pain includes neuropathic pain and pain from spasticity or cramps, while secondary pain is mainly nociceptive, occurring with the progression of muscle weakness and atrophy, prolonged immobility causing degenerative changes in joints and connective tissue, and long-term home mechanical ventilation. Prior to treatment, the exact patterns and causes of pain must first be identified, and the treatment should be tailored to each patient. Treatment options can be classified into pharmacological treatments, including nonsteroidal anti-inflammatory drugs, antiepileptic drugs, drugs for cramps or spasticity, and opioid; and nonpharmacological treatments, including positioning, splints, joint injections, and physical therapy. The development of standardized and specific assessment tools for pain-specific to ALS is required, as are further studies on treatments to reduce pain, diminish suffering, and improve the quality of life of patients with ALS.

참고문헌 (Reference)

1 Hirano YM, "Ventilator dependence and expressions of need : a study of patients with amyotrophic lateral sclerosis in Japan" 62 : 1403-1413, 2006

2 Baldinger R, "Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease" (4) : CD004157-, 2012

3 Galvin M, "The path to specialist multidisciplinary care in amyotrophic lateral sclerosis : a population-based study of consultations, interventions and costs" 12 : e0179796-, 2017

4 Åkerblom Y, "The multiple faces of pain in motor neuron disease : a qualitative study to inform pain assessment and pain management" 42 : 2123-2132, 2020

5 Yang J, "The modified WHO analgesic ladder : is it appropriate for chronic non-cancer pain?" 13 : 411-417, 2020

6 An R, "The evaluation of pain with nociceptive and neuropathic characteristics from three different perspectives in amyotrophic lateral sclerosis patients : a case controlled observational study in Southwestern China" 2021 : 5537892-, 2021

7 Wallace VC, "The evaluation of pain in amyotrophic lateral sclerosis : a case controlled observational study" 15 : 520-527, 2014

8 Poupon L, "Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin" 140 : 43-61, 2018

9 Ng L, "Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease" 1 : CD011776-, 2017

10 Anekar AA, "StatPearls" StatPearls Publishing 2022

11 Borasio GD, "Standards of palliative care for patients with amyotrophic lateral sclerosis : results of a European survey" 2 : 159-164, 2001

12 Truini A, "Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS" 262 : 1014-1018, 2015

13 Ho DT, "Shoulder pain in amyotrophic lateral sclerosis" 13 : 53-55, 2011

14 Miller RG, "Riluzole for amyotrophic lateral sclerosis(ALS)/motor neuron disease(MND)" 2012 : CD001447-, 2012

15 Moon ES, "Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy" 62 : 394-406, 2014

16 Majmudar S, "Rehabilitation in amyotrophic lateral sclerosis : why it matters" 50 : 4-13, 2014

17 Verschueren A, "Prevalence of spasticity and spasticity-related pain among patients with amyotrophic lateral sclerosis" 177 : 694-698, 2021

18 Hurwitz N, "Prevalence of pain in amyotrophic lateral sclerosis : a systematic review and meta-analysis" 22 : 449-458, 2021

19 Rivera I, "Prevalence and characteristics of pain in early and late stages of ALS" 14 : 369-372, 2013

20 Hayashi T, "Pressure ulcers in ALS patients on admission at a university hospital in Japan" 8 : 310-313, 2007

21 Palese F, "Predictors of diagnostic delay in amyotrophic lateral sclerosis : a cohort study based on administrative and electronic medical records data" 20 : 176-185, 2019

22 Miller RG, "Practice parameter update : the care of the patient with amyotrophic lateral sclerosis : multidisciplinary care, symptom management, and cognitive/behavioral impairment(an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology" 73 : 1227-1233, 2009

23 Bello-Haas VD, "Physical therapy for individuals with amyotrophic lateral sclerosis : current insights" 8 : 45-54, 2018

24 Raheja D, "Patient-reported problematic symptoms in an ALS treatment trial" 17 : 198-205, 2016

25 Mahoney CJ, "Pathophysiology and treatment of non-motor dysfunction in amyotrophic lateral sclerosis" 35 : 483-505, 2021

26 Borasio GD, "Palliative care in amyotrophic lateral sclerosis" 19 : 829-847, 2001

27 Stephens HE, "Pain in amyotrophic lateral sclerosis : patient and physician perspectives and practices" 17 : 21-29, 2015

28 Pagnini F, "Pain in amyotrophic lateral sclerosis : a psychological perspective" 33 : 1193-1196, 2012

29 Chiò A, "Pain in amyotrophic lateral sclerosis : a population-based controlled study" 19 : 551-555, 2012

30 Chiò A, "Pain in amyotrophic lateral sclerosis" 16 : 144-157, 2017

31 Taga A, "Pain at the onset of amyotrophic lateral sclerosis : a cross-sectional study" 186 : 105540-, 2019

32 Oliver D, "Opioid medication in the palliative care of motor neurone disease" 12 : 113-115, 1998

33 van Hecke O, "Neuropathic pain in the general population : a systematic review of epidemiological studies" 155 : 654-662, 2014

34 Caress JB, "Natural history of muscle cramps in amyotrophic lateral sclerosis" 53 : 513-517, 2016

35 National Institute for Health and Care Excellence (NICE), "NICE guideline. Motor neuron disease: assessment and management" NICE

36 Swash M, "Muscular cramp : causes and management" 26 : 214-221, 2019

37 Miller TM, "Muscle cramps" 32 : 431-442, 2005

38 Burrell JR, "Motor neuron dysfunction in frontotemporal dementia" 134 (134): 2582-2594, 2011

39 Belsh JM, "Misdiagnosis in patients with amyotrophic lateral sclerosis" 150 : 2301-2305, 1990

40 Moisset X, "Is there pain with neuropathic characteristics in patients with amyotrophic lateral sclerosis? : a cross-sectional study" 30 : 486-494, 2016

41 McClelland S 3rd, "Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis : efficacy and factors associated with pain relief" 37 : 396-398, 2008

42 Chiò A, "ISIS Survey : an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis" 246 (246): III1-III5, 1999

43 Cellura E, "Factors affecting the diagnostic delay in amyotrophic lateral sclerosis" 114 : 550-554, 2012

44 de Carvalho M, "Electrodiagnostic criteria for diagnosis of ALS" 119 : 497-503, 2008

45 Brooks BR, "El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis" 1 : 293-299, 2000

46 Brooks BR, "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis" 124 (124): 96-107, 1994

47 EFNS Task Force on Diagnosis, "EFNS guidelines on the clinical management of amyotrophic lateral sclerosis(MALS) : revised report of an EFNS task force" 19 : 360-375, 2012

48 Brettschneider J, "Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease" 2013 : CD005226-, 2013

49 Adelman EE, "Disparities in perceptions of distress and burden in ALS patients and family caregivers" 62 : 1766-1770, 2004

50 Paganoni S, "Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis(ALS)" 15 : 453-456, 2014

51 Househam E, "Diagnostic delay in amyotrophic lateral sclerosis : what scope for improvement?" 180 : 76-81, 2000

52 Turner M, "Diagnosing amyotrophic lateral sclerosis: clinical wisdom to facilitate faster diagnosis" Karger Publishers Limited 7-24, 2020

53 Pizzimenti A, "Depression, pain and quality of life in patients with amyotrophic lateral sclerosis : a cross-sectional study" 28 : 115-119, 2013

54 Ganzini L, "Correlates of suffering in amyotrophic lateral sclerosis" 52 : 1434-1440, 1999

55 Mayer NH, "Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion" 6 : S1-S13, 1997

56 Smart KM, "Clinical indicators of ‘nociceptive’, ‘peripheral neuropathic’ and ‘central’ mechanisms of musculoskeletal pain : a Delphi survey of expert clinicians" 15 : 80-87, 2010

57 Drake ME Jr, "Chronic pain syndrome in amyotrophic lateral sclerosis" 40 : 453-454, 1983

58 Jensen MP, "Chronic pain in persons with neuromuscular disease" 86 : 1155-1163, 2005

59 Hanisch F, "Characteristics of pain in amyotrophic lateral sclerosis" 5 : e00296-, 2015

60 Wigand B, "Characteristics of pain and the burden it causes in patients with amyotrophic lateral sclerosis : a longitudinal study" 23 : 284-291, 2022

61 Lopes LC, "Beyond weakness : Characterization of pain, sensory profile and conditioned pain modulation in patients with motor neuron disease : a controlled study" 22 : 72-83, 2018

62 Isaacs JD, "Amyotrophic lateral sclerosis with sensory neuropathy : part of a multisystem disorder?" 78 : 750-753, 2007

63 D’Ovidio F, "Amyotrophic lateral sclerosis incidence and previous prescriptions of drugs for the nervous system" 47 : 59-66, 2016

64 Dalla Bella E, "Amyotrophic lateral sclerosis causes small fiber pathology" 23 : 416-420, 2016

65 de Castro-Costa CM, "Amyotrophic lateral sclerosis : clinical analysis of 78 cases from Fortaleza(northeastern Brazil)" 57 (57): 761-774, 1999

66 Kiernan MC, "Amyotrophic lateral sclerosis" 377 : 942-955, 2011

67 Cruccu G, "A review of neuropathic pain : from guidelines to clinical practice" 6 (6): 35-42, 2017

68 Renton AE, "A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD" 72 : 257-268, 2011